Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wellpoint’s agency well-visit

This article was originally published in The Tan Sheet

Executive Summary

FDA still is "actively working on" Wellpoint Health Network's petition to forcibly switch all low- and non-sedating antihistamines from prescription status, FDA promises the insurer in an Aug. 5 letter. Wellpoint urged Acting FDA Commissioner Lester Crawford, PhD, to reply to its 1998 and 2000 petitions to switch Pfizer's Zyrtec, Schering-Plough's Clarinex and Aventis' Allegra over the counter in a recent letter (1"The Tan Sheet" July 26, 2004, p. 6)...

You may also be interested in...

Antihistamine Price Erosion Justifies Forced Switch – WellPoint

WellPoint Health Networks is continuing its campaign to urge a forced Rx-to-OTC switch of low-and non-sedating antihistamines cetirizine, fexofenadine and desloratadine

‘We Need Your COVID-19 Testing capacity’ UK Health Secretary Tells Life Science Firms

The UK has an “excellent but small diagnostics industry,” so it needs further testing support from related life science industries to tackle the COVID-19 crisis. One of the outcomes of this could be the creation of new big diagnostics industry players.

Drug/Device Combinations: New Position Paper Explains Notified Body Responsibilities

Medicinal products authorities will consider a medtech notified body opinion on the device element of a drug/device combination product. A new position paper explains how roles and responsibilities are shared between medtech and medicinal product experts.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts